

Yemin Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3818182/publications.pdf>

Version: 2024-02-01

23
papers

1,027
citations

516710

16
h-index

794594

19
g-index

27
all docs

27
docs citations

27
times ranked

1827
citing authors

#	ARTICLE	IF	CITATIONS
1	Fatty acid metabolism and drug resistance to EZH2 inhibition. <i>EBioMedicine</i> , 2022, 77, 103916.	6.1	1
2	Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines. <i>Gynecologic Oncology</i> , 2021, 160, 568-578.	1.4	21
3	Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. <i>Nature Cancer</i> , 2021, 2, 189-200.	13.2	36
4	ARID1A regulates R-loop associated DNA replication stress. <i>PLoS Genetics</i> , 2021, 17, e1009238.	3.5	40
5	Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. <i>Clinical Cancer Research</i> , 2020, 26, 4402-4413.	7.0	21
6	SWI/SNF Complex Mutations in Gynecologic Cancers: Molecular Mechanisms and Models. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2020, 15, 467-492.	22.4	47
7	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line. <i>PLoS ONE</i> , 2020, 15, e0240412.	2.5	1
8	Re-expression of SMARCA4/BRG1 in small cell carcinoma of ovary, hypercalcemic type (SCCOHT) promotes an epithelial-like gene signature through an AP-1-dependent mechanism. <i>ELife</i> , 2020, 9, .	6.0	19
9	Title is missing!. , 2020, 15, e0240412.		0
10	Title is missing!. , 2020, 15, e0240412.		0
11	Title is missing!. , 2020, 15, e0240412.		0
12	Title is missing!. , 2020, 15, e0240412.		0
13	Class I HDAC inhibitors enhance YB acetylation and oxidative stress to block sarcoma metastasis. <i>EMBO Reports</i> , 2019, 20, e48375.	4.5	78
14	DICER1 and FOXL2 Mutation Status Correlates With Clinicopathologic Features in Ovarian Sertoli-Leydig Cell Tumors. <i>American Journal of Surgical Pathology</i> , 2019, 43, 628-638.	3.7	62
15	DICER1 hotspot mutations in ovarian gynandroblastoma. <i>Histopathology</i> , 2018, 73, 306-313.	2.9	28
16	Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition. <i>Clinical Cancer Research</i> , 2018, 24, 1932-1943.	7.0	51
17	Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2767-2779.	4.1	50
18	The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type. <i>Journal of Pathology</i> , 2017, 242, 371-383.	4.5	78

#	ARTICLE	IF	CITATIONS
19	ARID1A-mutated ovarian cancers depend on HDAC6 activity. Nature Cell Biology, 2017, 19, 962-973.	10.3	173
20	Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. Journal of Pathology, 2016, 238, 389-400.	4.5	169
21	Recurrent DICER1 hotspot mutations in endometrial tumours and their impact on microRNA biogenesis. Journal of Pathology, 2015, 237, 215-225.	4.5	38
22	The Oncogenic Roles of DICER1 RNase IIIb Domain Mutations in Ovarian Sertoli-Leydig Cell Tumors. Neoplasia, 2015, 17, 650-660.	5.3	59
23	p53 Is Positively Regulated by miR-542-3p. Cancer Research, 2014, 74, 3218-3227.	0.9	50